Narcolepsy

Key Points

• Narcolepsy is a central nervous system hypersomnolence disorder with sudden, irresistible sleep episodes during waking hours.
• Type 1 narcolepsy involves low orexin levels and cataplexy (sudden muscle weakness triggered by emotions).
• Type 2 narcolepsy involves sudden sleep episodes without cataplexy and with normal orexin levels.
• Treatment can include wake-promoting agents (modafinil, pitolisant, solriamfetol) and sodium oxybate pathways for cataplexy/excessive daytime sleepiness.
• Sodium oxybate has major CNS/respiratory-depression and misuse risk and is dispensed through a restricted REMS pathway.

Pathophysiology

Narcolepsy is a central nervous system disorder of sleep-wake regulation. In type 1 narcolepsy, there is a deficiency of the neurotransmitter orexin (hypocretin), which plays a critical role in maintaining wakefulness. This deficiency is thought to result from autoimmune destruction of orexin-producing neurons in the hypothalamus. In type 2 narcolepsy, orexin levels are normal, and the exact pathophysiology is less well understood. The onset is most common between ages 10 and 25 years.

Classification

• Type 1: Sudden sleep episodes with cataplexy; low orexin levels; may include sleep paralysis and hallucinations.
• Type 2: Sudden daytime sleep episodes without cataplexy; normal orexin levels; common onset in adolescence.

Clinical Manifestations

• Excessive daytime sleepiness with sudden, irresistible “sleep attacks.”
• Cataplexy (type 1): sudden bilateral muscle weakness triggered by strong emotions (laughter, stress, excitement, fear).
• Hypnagogic or hypnopompic hallucinations (vivid sensory experiences at sleep onset or upon waking).
• Sleep paralysis (temporary inability to move or speak during transitions between sleep and wakefulness).
• Disrupted nighttime sleep.

Nursing Assessment

• Obtain detailed sleep history: frequency of daytime sleep episodes, triggers, associated symptoms.
• Assess for cataplexy: sudden muscle weakness episodes related to emotional stimuli.
• Evaluate impact on daily functioning: work performance, driving safety, social relationships.
• Review polysomnography and multiple sleep latency test (MSLT) results.
• Assess safety risks: falls from cataplexy, motor vehicle accidents from sleep attacks.

Nursing Interventions

• Administer prescribed wake-promoting therapy (for example modafinil, pitolisant, or solriamfetol) for excessive daytime sleepiness.
• Administer prescribed sodium oxybate for cataplexy and nighttime sleep consolidation, and verify restricted-program safety workflows.
• Educate about safety: avoid driving or operating machinery during periods of sleepiness; plan short scheduled naps.
• Promote regular sleep-wake schedules and good sleep hygiene.
• Provide emotional support; narcolepsy can significantly impact quality of life and self-esteem.
• Encourage wearing medical alert identification.
• Reinforce avoidance of alcohol, sedative-hypnotics, and other CNS depressants with sodium-oxybate therapy because respiratory depression and reduced consciousness risk increase.
• Screen and escalate for mood changes, depression, suicidality, parasomnias, or confusion during narcolepsy pharmacotherapy.

Related Concepts

• obstructive-sleep-apnea - Another common sleep disorder to differentiate.
• sleep-disorders-overview-for-nursing-triage - Broader sleep disorder classification.
• seizures-and-epilepsy - Differential diagnosis for sudden loss of muscle tone.
• Safety - Fall and accident prevention in narcolepsy clients.
• Coping And Stress Tolerance - Psychosocial impact of chronic neurological disorder.

Self-Check

1. What neurotransmitter deficiency is associated with type 1 narcolepsy?
2. How does cataplexy differ from a seizure?
3. Why is safety education critical for clients diagnosed with narcolepsy?